Top ▲
Target id: 3056
Nomenclature: Plasmodium falciparum prolyl-tRNA synthetase
Abbreviated Name: PfcPRS
Family: Aminoacyl-tRNA synthetases
Gene and Protein Information | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Plasmodium falciparum 3D7 | - | 746 | PRS | proline--tRNA ligase | ||
Gene and Protein Information Comments | ||||||
The Plasmodium genome encodes two forms of prolyl-tRNA synthetase, one found in the cytoplasm (PfcPRS, described here) and one in the apicoplast (PfaPRS, encoded by PF3D7_0925300). |
Previous and Unofficial Names |
Pf3D7_12_v3:589,729..593,777(-) | PfProRS | PFL0670c | Plasmodium falciparum proline--tRNA ligase |
Database Links | |
Alphafold | Q8I5R7 (Pf3D7) |
ChEMBL Target | CHEMBL3301560 (Pf3D7) |
PlasmoDB | PF3D7_1213800 (Pf3D7) |
SynPHARM | 85927 (in complex with halofuginone) |
UniProtKB | Q8I5R7 (Pf3D7) |
Selected 3D Structures | |||||||||||||
|
|||||||||||||
|
Whole Organism Assay Data Linked to This Target | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Malaria Pharmacology Comments |
PfcPRS is ranked as a "High Priority" target in the Malaria Drug Accelerator (MalDA) portfolio [2]. |
1. Derbyshire ER, Mazitschek R, Clardy J. (2012) Characterization of Plasmodium liver stage inhibition by halofuginone. ChemMedChem, 7 (5): 844-9. [PMID:22438279]
2. Forte B, Ottilie S, Plater A, Campo B, Dechering KJ, Gamo FJ, Goldberg DE, Istvan ES, Lee M, Lukens AK et al.. (2021) Prioritization of Molecular Targets for Antimalarial Drug Discovery. ACS Infect Dis, 7 (10): 2764-2776. [PMID:34523908]
3. Herman JD, Pepper LR, Cortese JF, Estiu G, Galinsky K, Zuzarte-Luis V, Derbyshire ER, Ribacke U, Lukens AK, Santos SA et al.. (2015) The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a dual-stage target of febrifugine and its analogs. Sci Transl Med, 7 (288): 288ra77. [PMID:25995223]
4. Jain V, Kikuchi H, Oshima Y, Sharma A, Yogavel M. (2014) Structural and functional analysis of the anti-malarial drug target prolyl-tRNA synthetase. J Struct Funct Genomics, 15 (4): 181-90. [PMID:25047712]
5. Jain V, Yogavel M, Oshima Y, Kikuchi H, Touquet B, Hakimi MA, Sharma A. (2015) Structure of Prolyl-tRNA Synthetase-Halofuginone Complex Provides Basis for Development of Drugs against Malaria and Toxoplasmosis. Structure, 23 (5): 819-829. [PMID:25817387]
6. Okaniwa M, Shibata A, Ochida A, Akao Y, White KL, Shackleford DM, Duffy S, Lucantoni L, Dey S, Striepen J et al.. (2021) Repositioning and Characterization of 1-(Pyridin-4-yl)pyrrolidin-2-one Derivatives as Plasmodium Cytoplasmic Prolyl-tRNA Synthetase Inhibitors. ACS Infect Dis, 7 (6): 1680-1689. [PMID:33929818]
Aminoacyl-tRNA synthetases: Plasmodium falciparum prolyl-tRNA synthetase. Last modified on 29/03/2022. Accessed on 06/12/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetomalariapharmacology.org/GRAC/ObjectDisplayForward?objectId=3056.